Shingrix schedule status change
Effective July 26, 2021, the non-live recombinant herpes zoster vaccine has been granted NAPRA Schedule II status, and the National Drug Schedules for non-live recombinant herpes zoster vaccines, such as Shingrix®, has been updated.
This change to Schedule II allows more flexibility and increased access to Shingrix® for patients who are not eligible for the publicly funded shingles immunization program by not requiring a prescription from the patient’s primary care provider prior to the dispensing of a non-live recombinant herpes zoster vaccine.
About this tool
The Pharmacist Clinical Tool for Initiating Shingrix Discussions tool has been developed by OPA with a grant provided by GlaxoSmithKline Canada (GSK). The information provided in this document is intended to assist pharmacists with initiating discussions with patients about recombinant herpes zoster vaccines but does not replace professional judgement and responsibilities.